Today Anthropic is hosting its first “AI for Science” virtual briefing, bringing together pharma executives, biotech founders, and research institutions to show how Claude is being embedded into scientific workflows. The event, which airs at 10:00am PST, is less an announcement than a signal: Anthropic is serious about making Claude the infrastructure of science, not just a chatbot for scientists.

The timing is deliberate. Over the past few months, Anthropic has assembled a credible life sciences stack — and today is the public reveal of where that work has landed.

The BMS Deal Is the Headline

The anchor partnership in Anthropic’s science push is Bristol Myers Squibb, one of the world’s largest pharmaceutical companies. On May 20, 2026, BMS announced it would deploy Claude Enterprise to more than 30,000 employees across research, drug development, manufacturing, and commercial operations.

That scope is meaningful. Most enterprise AI deployments in pharma have been isolated pilots — a research team here, a regulatory affairs function there. BMS is treating Claude as a platform, not a project. Chief Digital and Technology Officer Greg Meyers described the goal as unlocking value “still trapped behind decades of data silos.”

Specific applications include Claude writing regulatory reports from clinical trial data, accelerating manufacturing quality review, and supporting internal knowledge search across the company’s vast documentation base. BMS is also deploying Claude Code to its engineering and AI teams, compressing the development cycles that underpin new drug delivery tools.

Anthropic Has Been Buying Its Way Into Biology

Two months before the BMS announcement, Anthropic made a $400 million acquisition that drew less attention than it deserved. In April 2026, the company acquired Coefficient Bio, a stealth drug discovery startup, giving Anthropic direct operational expertise in drug target selection and clinical regulatory strategy.

This was not a talent acquisition. Coefficient Bio brought the workflows, the domain knowledge, and — critically — the hard-won understanding of what it takes to move a drug through regulatory approval. Anthropic did not just want a scientific advisor; it wanted people who have been inside the machine.

That acquisition was followed in June by John Jumper joining Anthropic from Google DeepMind. Jumper won a Nobel Prize in 2024 as co-creator of AlphaFold, the AI system that solved the 50-year-old protein folding problem. His move to Anthropic is the kind of talent signal that institutional buyers notice.

The Technical Credibility Problem — And How Anthropic Is Solving It

Alongside the partnerships and hires, Anthropic’s research team has been quietly addressing a core problem in biological AI: accuracy.

In June 2026, Anthropic published “Paving the Way for Agents in Biology,” a paper that created VirBench — a benchmark of 120 viral sequence retrieval queries across 40 pathogens. The finding was blunt: without deterministic data access tools, AI agents hallucinate on biological queries at rates that make them unusable in research. Claude Sonnet 4 scored 16.9% accuracy without the right infrastructure. With a deterministic execution layer (gget virus), accuracy jumped above 90% across all tested models.

The lesson is not that AI is bad at biology. It is that biological data infrastructure was built for human browsers, not agents. Fix the infrastructure and the models perform. This is the kind of foundational work that makes enterprise pharma buyers comfortable committing at scale.

What This Means for Business

If you work in a knowledge-intensive, regulated industry, the BMS deployment is the pattern to watch. AI is not creeping into pharma through productivity tools — it is being embedded into the core workflows that determine what gets developed, how fast, and at what cost. Drug discovery timelines that once took weeks are being compressed to hours.

If you are evaluating enterprise AI vendors, Anthropic’s life sciences push illustrates a strategy worth understanding: targeted vertical depth, not horizontal breadth. Rather than building a generalist tool and hoping it works in pharma, Anthropic is acquiring domain expertise, building domain-specific infrastructure, and hiring domain credibility.

For anyone in data-driven organizations, the biology agents paper contains a broadly applicable insight. The bottleneck in enterprise AI is rarely the model — it is the data infrastructure. Agents that cannot reliably access structured, authoritative data will hallucinate. Fixing your data layer before your agent layer is not optional.

Anthropic’s AI for Science briefing today will showcase customer outcomes from pharma, biotech, and research institutions. Whether it produces new product announcements or focuses on deployment stories, the underlying message is clear: Claude is being positioned as the backbone of scientific research at scale. For industries where the stakes are literally life-and-death, that is an ambitious and consequential bet.